 Hoth Therapeutics, Inc. NASDAQ: HOTH a biopharmaceutical company, today announced that it has expanded its sponsored research agreement with the George Washington University GW to explore the potential use of WEG232 for topical andor systemic therapy to counter the dermatological related side-effects of chemotherapy and immunotherapy in cancer patients. 